Q2 2022

Filed Aug 11, 2022 · 10-Q · 42 days after period end · 0001410578-22-002292

Q2 2022 · 10-Q

Revenue

$790.51K

no prior Q2 2021 on file

Net Income

-$9.24M

N/M vs Q2 2021

EPS Diluted

-$1.11

N/M vs Q2 2021

Operating Income-$5,268,537N/M

Operating Cash Flow

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	$790.51K	—	$466.79K	$0.00
Net Income	-$9.24M	-$10.91M	-$6.34M	-$5.57M
EPS Diluted	-$1.11	-$0.13	-$0.14	-$0.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR